VISTIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vistide, and what generic alternatives are available?
Vistide is a drug marketed by Gilead Sciences Inc and is included in one NDA.
The generic ingredient in VISTIDE is cidofovir. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cidofovir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vistide
A generic version of VISTIDE was approved as cidofovir by MYLAN INSTITUTIONAL on June 27th, 2012.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VISTIDE?
- What are the global sales for VISTIDE?
- What is Average Wholesale Price for VISTIDE?
Summary for VISTIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Clinical Trials: | 11 |
| Patent Applications: | 4,403 |
| What excipients (inactive ingredients) are in VISTIDE? | VISTIDE excipients list |
| DailyMed Link: | VISTIDE at DailyMed |
Recent Clinical Trials for VISTIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Centro de Investigación en. Enfermedades Infecciosas, Mexico | Phase 2 |
| Gilead Sciences | Phase 1 |
| M.D. Anderson Cancer Center | Phase 1 |
US Patents and Regulatory Information for VISTIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | VISTIDE | cidofovir | INJECTABLE;INJECTION | 020638-001 | Jun 26, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VISTIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | VISTIDE | cidofovir | INJECTABLE;INJECTION | 020638-001 | Jun 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for VISTIDE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences International Limited | Vistide | cidofovir | EMEA/H/C/000121 Vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Vistide should be used only when other agents are considered unsuitable., |
Withdrawn | no | no | no | 1997-04-23 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for VISTIDE
See the table below for patents covering VISTIDE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Netherlands | 970036 | ⤷ Sign Up | |
| Luxembourg | 90155 | ⤷ Sign Up | |
| South Korea | 950004179 | ⤷ Sign Up | |
| Finland | 86856 | ⤷ Sign Up | |
| Canada | 1340856 | PURINES ETPYRIMIDINES N-PHOSPHONYLMETHOXYALKYLIQUES; LEUR EMPLOI A DES FINS THERAPEUTIQUES (N-PHOSPHONYLMETHOXYALKYL PYRIMIDINES AND PURINES AND THERAPEUTIC APPLICATION THEREOF) | ⤷ Sign Up |
| Spain | 2036194 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VISTIDE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0253412 | 63/1997 | Austria | ⤷ Sign Up | PRODUCT NAME: CIDOFOVIR; REGISTRATION NO/DATE: K (97) 1176 19970423 |
| 0253412 | 97C0105 | Belgium | ⤷ Sign Up | PRODUCT NAME: CIDOFOVIR; REGISTRATION NO/DATE: EU/1/97/037/001 19970423 |
| 0253412 | C970036 | Netherlands | ⤷ Sign Up | PRODUCT NAME: CIDOFOVIR,DESGEWENST IN DE VORM VAN EEN ZOUT MET AMMONIA,EEN ALKALIMETAAL OF EEN AMINE; REGISTRATION NO/DATE: EU/1/97/037/001 19970423 |
| 0253412 | SPC/GB97/083 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: CIDOFOVIR; REGISTERED: UK EU/1/97/037/001 19970423 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
